This is the first competing renewal application of the Vanderbilt-Ingram Cancer Center (VICC) Breast Cancer SPORE Grant. It is comprised of investigators with expertise in cellular signaling and molecular biology, breast pathology, medical, surgical, and radiation oncology, clinical trial design, epidemiology and population studies, mass spectrometry, imaging, biostatistics, and biomedical informatics. We have made progress in our previous funding cycle, have established productive collaborations with other SPOREs and other national and international groups, and have firmly established a true multidisciplinary program which we believe will be productive in the years to come. In this competing renewal we propose four bi-directional translational projects addressing basic, clinical and population research questions in human breast cancer. ? ? Project 1: Resistance to antiestrogen therapy in hormone receptor-positive breast cancer (Carlos L. Arteaga, MD) Project 2: p63/p73 signaling axis as a target for treatment of triple negative breast cancer (Jennifer Pietenpol, PhD) Project 3: Cellular mechanisms of bone quality in metastatic breast cancer (Gregory Mundy, MD) Project 4: Genetic predictors of progression of premalignant breast disease (Jeffrey Smith, MD, PhD and William Dupont, PhD) ? ? In our opinion, these projects meet the eligibility criteria set forth in the SPORE guidelines. They span themes involving discovery of mechanisms of antiestrogen resistance, determining pathogenic mechanisms and new therapies for triple negative breast cancer, identifying genetic markers of breast cancer risk in women with preneoplastic mammary lesions, and investigating mechanisms and biomarkers of bone quality in patients with metastatic breast cancer. The SPORE has access to a substantial breast cancer population and an established record of accrual to clinical trials. The leadership of the VICC and VUMC has provided strong Institutional support for the success of the individuals involved in this application. A significant amount of support has been promised by the Institution in the event of successful funding of this application. Meritorious research applications for developmental (pilot) projects will be solicited from throughout the VICC, VUMC, and Meharry Medical College. The SPORE has supported and will continue to identify and support the careers of young investigators starting a career in breast cancer and of more established investigators adding a promising domain in breast cancer research to their programs. To support the research aims in the translational research projects, we propose five shared Core Resources. Each of these cores supports at least 3 projects in this competing renewal application. They are Administration & Outreach, Tissue, Clinical, Biostatistics, and Imaging Cores. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098131-06
Application #
7504833
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Kuzmin, Igor A
Project Start
2003-08-07
Project End
2013-05-31
Budget Start
2008-09-11
Budget End
2009-05-31
Support Year
6
Fiscal Year
2008
Total Cost
$2,300,000
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241

Showing the most recent 10 out of 341 publications